En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial


Por: Gallioli, A, Diana, P, Fontana, M, Territo, A, Rodriguez-Faba, O, Gaya, JM, Sanguedolce, F, Huguet, J, Mercade, A, Piana, A, Aumatell, J, Bravo-Balado, A, Algaba, F, Palou, J, Breda, A

Publicada: 1 ago 2022
Resumen:
Background: It has been proposed that en bloc resection of bladder tumor (ERBT) improves the quality of tumor resection. A recent international collaborative consensus statement on ERBT underlined the lack of high-quality prospective studies precluding the achievement of solid conclusion on ERBT.Objective: To compare conventional transurethral resection of bladder tumor (cTURBT) and ERBT.Design, setting, and participants: This study (NCT04712201) was a prospective, randomized, noninferiority trial enrolling patients diagnosed with bladder cancer (BC) undergoing endoscopic intervention. Inclusion criteria were: tumor size <= 3 cm, three or fewer lesions, and no sign of muscle invasion and/or ureteral involvement. For a noninferiority rate in BC staging of 5% (a risk 2.5%; b risk 20%), a total of 300 subjects were randomized to ERBT treatment at a 1:1.5 allocation ratio.Intervention: TURBT and ERBT.Outcome measurements and statistical analysis: The primary outcome was the presence of detrusor muscle at final histology. Secondary outcomes include BC staging, T1 substaging, artifacts, complications, the rate of adjuvant treatment, and oncological outcomes.Results and limitations: From April 2018 to June 2021, 300 patients met the inclusion criteria. Of these, 248 (83%) underwent the assigned intervention: 108 patients (44%) underwent cTURBT and 140 (57%) underwent ERBT. The rate of detrusor muscle presence for ERBT was noninferior to that for TURBT (94% vs 95%; p = 0.8). T1 substaging was feasible in 80% of cTURBT cases versus 100% of ERBT cases (p = 0.02). Complication rates, rates of postoperative adjuvant treatment, catheterization time, and hospital stay were comparable between the two groups (p > 0.05). The recurrence rate at median follow-up of 15 mo (interquartile range 7-28) was 18% for cTURBT versus 13% for ERBT (p = 0.16). Limitations include the single high-volume institution and the short-term follow-up. Conclusions: Our study has the highest level of evidence for comparison of ERBT versus TURBT. ERBT was noninferior to TURBT for BC staging. The rate of T1 substaging feasibilityPatient summary: We compared two techniques for removing tumors from the bladder. The en bloc technique removes the tumor in one piece and is not inferior to the conventional method in terms of the quality of the surgical resection and cancer staging assessment. (c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Filiaciones:
Gallioli, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Diana, P:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

 Human Res Hosp, IRCCS, Dept Urol, Rozzano, Italy

Fontana, M:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Territo, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Rodriguez-Faba, O:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Gaya, JM:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Sanguedolce, F:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Huguet, J:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Mercade, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Piana, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Aumatell, J:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Bravo-Balado, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

Algaba, F:
 Autonomous Univ Barcelona, Dept Pathol, Fundacio Puigvert, Barcelona, Spain

Palou, J:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

 Autonomous Univ Barcelona, Dept Surg, Barcelona, Spain

Breda, A:
 Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

 Autonomous Univ Barcelona, Dept Surg, Barcelona, Spain
ISSN: 25889311





European Urology Oncology
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 5 Número: 4
Páginas: 440-448
WOS Id: 000843280400009
ID de PubMed: 35618567

MÉTRICAS